Hospital
Forrest County General Hospital
Forrest County General Hospital was paid $9.51M by Medicaid between Jan 2018 and Dec 2024, across 136 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoFORREST COUNTY GENERAL HOSPITAL
COLUMBIA, MS 39429
COLUMBIA, MS 39429
33aNPI1427320993assigned 01/31/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.51M
24GClaims297,615
24DCodes billed136
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#37 of 77
Median peer was paid$8.23M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HESTER, BEN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,535 | $1.45M | |
| 2019 | 45,562 | $1.44M | |
| 2020 | 31,551 | $889K | |
| 2021 | 35,268 | $1.19M | |
| 2022 | 46,877 | $1.52M | |
| 2023 | 49,947 | $1.68M | |
| 2024incomplete | 38,875 | $1.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 20,430 | 17,714 | $2.64M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 8,077 | 7,206 | $1.18M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 8.2% | 8,269 | 7,217 | $780K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.1% | 3,422 | 3,042 | $584K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 4,192 | 3,778 | $351K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.0% | 5,257 | 4,442 | $288K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 1,467 | 1,321 | $212K |
| 87634 | 2.2% | 5,243 | 4,429 | $210K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.2% | 3,290 | 1,688 | $210K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.2% | 1,113 | 975 | $207K |
| G0378 | Hospital observation service, per hour | 1.9% | 723 | 548 | $184K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 7,544 | 6,388 | $177K |
124 more codes
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.7% | 5,433 | $164K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 1,707 | $140K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 3,393 | $129K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 7,697 | $128K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 3,376 | $128K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 4,956 | $127K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 1,324 | $126K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 4,123 | $117K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 3,173 | $116K |
| 80053 | Comprehensive metabolic panel | 1.0% | 16,740 | $96K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,955 | $89K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,053 | $81K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,094 | $79K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,641 | $78K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,237 | $76K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,831 | $72K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,371 | $67K |
| 74018 | <1% | 741 | $41K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,952 | $39K |
| 73562 | <1% | 969 | $34K | |
| 87430 | <1% | 2,735 | $33K | |
| 84484 | <1% | 5,945 | $30K | |
| 73630 | <1% | 702 | $28K | |
| 72100 | <1% | 572 | $28K | |
| 83880 | <1% | 2,430 | $27K | |
| 82553 | <1% | 5,755 | $24K | |
| 81001 | <1% | 12,219 | $21K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,347 | $21K |
| 81025 | <1% | 3,594 | $20K | |
| 80061 | Lipid panel | <1% | 2,000 | $18K |
| 82550 | <1% | 6,677 | $18K | |
| 87040 | <1% | 2,826 | $16K | |
| 73610 | <1% | 328 | $15K | |
| 73130 | <1% | 367 | $14K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,078 | $14K |
| 87081 | <1% | 2,557 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,206 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,569 | $13K |
| 83605 | <1% | 2,923 | $11K | |
| 87186 | <1% | 2,135 | $11K | |
| 87077 | <1% | 2,193 | $11K | |
| 83690 | <1% | 2,936 | $11K | |
| 83735 | <1% | 3,588 | $10K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 211 | $10K |
| 73030 | <1% | 302 | $10K | |
| 74022 | <1% | 169 | $9K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 239 | $8K |
| 82962 | <1% | 4,498 | $7K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 86 | $6K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 36 | $5K |
| 82150 | <1% | 1,459 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 258 | $5K |
| 85610 | <1% | 2,036 | $4K | |
| 85379 | <1% | 1,049 | $4K | |
| 73110 | <1% | 79 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 80 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 160 | $4K |
| 87420 | <1% | 313 | $4K | |
| 85730 | <1% | 1,258 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 57 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 84 | $3K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 18 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,024 | $2K |
| 82607 | <1% | 251 | $2K | |
| 84439 | <1% | 355 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $2K |
| 86140 | <1% | 582 | $2K | |
| 86900 | <1% | 42 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 96 | $1K |
| 97014 | <1% | 113 | $1K | |
| 80069 | <1% | 500 | $1K | |
| 85027 | <1% | 225 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,864 | $1K |
| 73502 | <1% | 40 | $943.79 | |
| 82803 | <1% | 94 | $885.79 | |
| 73090 | <1% | 18 | $831.90 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 45 | $816.28 |
| 93971 | <1% | 26 | $802.62 | |
| 36600 | <1% | 26 | $780.21 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 35 | $726.34 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 35 | $720.34 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 42 | $703.28 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 44 | $502.64 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 341 | $468.00 |
| 86901 | <1% | 42 | $402.20 | |
| 86308 | <1% | 76 | $356.87 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,649 | $299.61 |
| 97162 | <1% | 13 | $285.32 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,155 | $279.73 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 217 | $204.67 |
| 86738 | <1% | 13 | $186.30 | |
| 82746 | <1% | 15 | $167.39 | |
| 85651 | <1% | 86 | $163.38 | |
| 84703 | <1% | 26 | $162.56 | |
| 86803 | <1% | 14 | $123.73 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 867 | $123.07 |
| 86850 | <1% | 13 | $119.43 | |
| 36592 | <1% | 8,989 | $106.72 | |
| 85007 | <1% | 29 | $95.90 | |
| 87070 | <1% | 16 | $85.36 | |
| 82728 | <1% | 13 | $74.12 | |
| 84550 | <1% | 25 | $69.76 | |
| 82043 | <1% | 14 | $69.36 | |
| 82140 | <1% | 34 | $68.58 | |
| 82565 | <1% | 18 | $67.76 | |
| 87205 | <1% | 30 | $65.28 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,869 | $62.95 |
| A9270 | Non-covered item or service | <1% | 6,630 | $45.15 |
| 96376 | <1% | 379 | $35.10 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 83 | $33.28 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 338 | $14.86 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 89 | $10.80 |
| 84145 | <1% | 45 | $5.44 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 179 | $4.25 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 17 | $1.46 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 198 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 91 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 132 | $0.00 |
| 90715 | 0% | 19 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 29 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 107 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 215 | $0.00 |
| 94760 | 0% | 133 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHESTER, BEN (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Forrest County General Hospital | Hattiesburg, MS | $81.63M |
| Forrest County General Hospital | Picayune, MS | $21.66M |
| Walthall General Hospital | Tylertown, MS | $6.16M |
| Forrest County General Hospital | Prentiss, MS | $3.80M |
| Forrest County General Hospital | Poplarville, MS | $3.74M |
| Forrest County General Hospital | Poplarville, MS | $2.80M |
| Forrest County General Hospital | Picayune, MS | $2.76M |
| Forrest County General Hospital | Richton, MS | $1.58M |
| Forrest County General Hospital | Richton, MS | $1.36M |
| Forrest County General Hospital | Columbia, MS | $1.03M |
| Walthall General Hospital | Tylertown, MS | $953K |
| Forrest General Hospital | Hattiesburg, MS | $850K |
| Forrest County General Hospital | Poplarville, MS | $253K |
| FGH Physician Billing | Hattiesburg, MS | $224K |
| Forrest County General Hospital | Prentiss, MS | $204K |
| Forrest County General Hospital | Picayune, MS | $65K |
| FGH Trauma Surgery Clinic | Hattiesburg, MS | $47K |
| Forrest County General Hospital | Poplarville, MS | $22K |
| Forrest County General Hospital | Richton, MS | $18K |
| Walthall General Hospital | Tylertown, MS | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.